CEO of AIM, Thomas K. Equels, highlights their robust cash p...
CEO of AIM, Thomas K. Equels, highlights their robust cash position enabling strong clinical and operational performance. He also brings attention to the company's ovarian and pancreatic cancer programs, forecasting value-boosting milestones ahead from them.
Press Release: AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4352Followers
0Following
9558Visitors
Follow